Alzamend Neuro is trading 5.7% down at $1.33 on November 9, 2026, with no clear company-specific explanation identified. - The latest company news found predates this session. - The investor-relations site lists a November 14–18 neuroscience meeting and planned presentation of Phase 1/2A imaging data; the upcoming event does not establish a reason for the drop. - Major indexes are higher, and no trading-volume details were provided.